Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)]

NCT00057720 is registered in ClinicalTrials.gov with Telik as lead sponsor.

NCT NCT00057720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00057720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)]
Lead sponsor
Telik
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2003
Completion date
December 31, 2006
Enrollment
440
Sites
320

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms